```
Trying 3106016892...Open

Welcome to STN International!  Enter x:x
LOGINID:ssspta1644pnh
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Sep 29   The Philippines Inventory of Chemicals and Chemical
                   Substances (PICCS) has been added to CHEMLIST
 NEWS  3  Oct 27   New Extraction Code PAX now available in Derwent
                   Files
 NEWS  4  Oct 27   SET ABBREVIATIONS and SET PLURALS extended in
                   Derwent World Patents Index files
 NEWS  5  Oct 27   Patent Assignee Code Dictionary now available
                   in Derwent Patent Files
 NEWS  6  Oct 27   Plasdoc Key Serials Dictionary and Echoing added to
                   Derwent Subscriber Files WPIDS and WPIX
 NEWS  7  Nov 29   Derwent announces further increase in updates for DWPI
 NEWS  8  Dec  5   French Multi-Disciplinary Database PASCAL Now on STN
 NEWS  9  Dec  5   Trademarks on STN - New DEMAS and EUMAS Files
 NEWS 10  Dec 15   2001 STN Pricing
 NEWS 11  Dec 17   Merged CEABA-VTB for chemical engineering and
                   biotechnology
 NEWS 12  Dec 17   Corrosion Abstracts on STN
 NEWS 13  Dec 17   SYNTHLINE from Prous Science now available on STN
 NEWS 14  Dec 17   The CA Lexicon available in the CAPLUS and CA files
 NEWS 15  Jan 05   AIDSLINE is being removed from STN
 NEWS 16  Feb 06   Engineering Information Encompass files have new names

 NEWS EXPRESS  FREE UPGRADE 5.0e FOR STN EXPRESS 5.0 WITH DISCOVER!
               (WINDOWS) NOW AVAILABLE
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:38:19 ON 12 FEB 2001

=> file medline embase biosis scisearch caplus

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

FULL ESTIMATED COST 0.15 0.15

FILE 'MEDLINE' ENTERED AT 10:38:50 ON 12 FEB 2001

FILE 'EMBASE' ENTERED AT 10:38:50 ON 12 FEB 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:38:50 ON 12 FEB 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'SCISEARCH' ENTERED AT 10:38:50 ON 12 FEB 2001
COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

FILE 'CAPLUS' ENTERED AT 10:38:50 ON 12 FEB 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

=> s minor histocompatibility antigen

L1 2960 MINOR HISTOCOMPATIBILITY ANTIGEN

=> s l1 and derivative

L2 19 L1 AND DERIVATIVE

=> dup remove l2

PROCESSING COMPLETED FOR L2
L3 13 DUP REMOVE L2 (6 DUPLICATES REMOVED)

=> d 13

L3 ANSWER 13 OF 13 MEDLINE DUPLICATE 3
AN 86002336 MEDLINE
DN 86002336
TI **Minor histocompatibility antigens** are developmentally regulated on murine embryonal carcinoma cells and their early differentiated **derivatives**.
AU Avner P; Simmler M C
SO CELL DIFFERENTIATION, (1985 Aug) 17 (2) 115-23.
Journal code: CQ6. ISSN: 0045-6039.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198601

=> d l13 all 1-13

L13 NOT FOUND
The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s 13

L4 13 L3

=> d l4 all 1113

13 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):1-13

L4 ANSWER 1 OF 13 MEDLINE
AN 2000269805 MEDLINE
DN 20269805
TI Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation.
AU Georges G E; Storb R; Thompson J D; Yu C; Gooley T; Bruno B; Nash R A
CS Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, WA 98109-1024, USA.. ggeorges@fhcrc.org
NC DK42716 (NIDDK)
CA15704 (NCI)
CA78902 (NCI)
+
SO BLOOD, (2000 May 15) 95 (10) 3262-9.
Journal code: A8G. ISSN: 0006-4971.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
EM 200008
EW 20000803
AB Development of nontoxic and nonmyeloablative regimens for allogeneic hematopoietic stem-cell transplantation will decrease transplantation-related mortality caused by regimen-related toxic effects. In pursuit of this goal, a dog model of stable mixed hematopoietic chimerism was established in which leukocyte-antigen-identical litter mates are given sublethal total-body irradiation (2 Gy) before stem-cell transplantation and immunosuppression with mycophenolate mofetil and cyclosporine afterward. In the current study, we examined whether donor lymphocyte infusion (DLI) could be used as adoptive immunotherapy to convert mixed to complete donor chimerism. First, 8 mixed chimeras were given unmodified DLI between day 36 and day 414 after stem-cell transplantation. After a 10- to 47-week follow-up period, there were no significant changes in the percentage of donor engraftment. Next, we immunized the donor to the **minor histocompatibility antigens** (mHA) of the recipient by means of repeated skin grafting. Lymphocytes from the mHA-sensitized donor were infused between day 201 and day 651 after transplantation. All 8 recipients of mHA-sensitized DLI had conversion to greater than 98% donor chimerism within 2 to 12 weeks of the infusion. Complications from mHA-sensitized DLI included graft-versus-host disease in 2 dogs and marrow aplasia in 1. These results showed that the low-dose transplant regimen establishes immune tolerance, and mHA-sensitized DLI is required to break tolerance, thereby converting mixed to complete donor chimerism. We propose that mixed chimerism established after nonmyeloablative allogeneic stem-cell transplantation provides a platform

for adoptive immunotherapy that has clinical potential in the treatment of patients with malignant diseases.

CT Check Tags: Animal; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
Cyclosporine: AD, administration & dosage
Dogs
*Hematopoietic Stem Cell Transplantation
Immunosuppressive Agents: AD, administration & dosage
*Immunotherapy, Adoptive
Isoantigens
Lymphocyte Transfusion
*Lymphocytes: IM, immunology
Mycophenolic Acid: AA, analogs & derivatives
Mycophenolic Acid: AD, administration & dosage
Myeloablative Agonists: TU, therapeutic use
Tissue Donors
*Transplantation Chimera
Transplantation Immunology

RN 128794-94-5 (RS 61443); 24280-93-1 (Mycophenolic Acid); 59865-13-3 (Cyclosporine)

CN 0 (Immunosuppressive Agents); 0 (Isoantigens); 0 (Myeloablative Agonists)

L4 ANSWER 2 OF 13 MEDLINE

AN 97256599 MEDLINE

DN 97256599

TI Identification of the rat maternally transmitted **minor histocompatibility antigen.**

AU Bhuyan P K; Young L L; Lindahl K F; Butcher G W

CS Howard Hughes Medical Institute, The University of Texas Southwestern Medical Center, Dallas 75235, USA.

SO JOURNAL OF IMMUNOLOGY, (1997 Apr 15) 158 (8) 3753-60.
Journal code: IFB. ISSN: 0022-1767.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals

EM 199707

EW 19970702

AB The rat maternally transmitted Ag has been previously described as a minor histocompatibility Ag composed of a mitochondrially transmitted factor (MTF) and the RT1.Aa MHC class I molecule. We compared the DNA sequences of the 13 mitochondrial open reading frames from different rat strains and identified four coding polymorphisms that correlated with this MTF. We used synthetic 17-mer peptides spanning the polymorphisms to sensitize appropriate target cells in lymphocytotoxicity assays and found that the MTF is derived from an internal region of ATPase 6. A tridecameric **derivative** of the ATPase 6 17 mer (termed 13N3E) could sensitize RT1.Aa-expressing target cells at picomolar concentrations and, when present on such cells, could compete fully with the natural ligand in cold-target competition assays. Comparing the 13N3E peptide with the known peptide-binding requirements of RT1.Aa suggested two possible binding conformations, placing either an internal or a C-terminal arginine in the F pocket of the peptide-binding groove. Arguments favoring a "bulging" conformation, with N- and C-terminal residues bound into their conserved pockets, are discussed.

CT Check Tags: Animal; Female; Support, Non-U.S. Gov't
Amino Acid Sequence
DNA, Mitochondrial: GE, genetics
*Immunity, Maternally-Acquired
Minor Histocompatibility Antigens: GE, genetics
***Minor Histocompatibility Antigens: IM, immunology**
Molecular Sequence Data
Pregnancy
Rats
Rats, Inbred Strains
CN 0 (DNA, Mitochondrial); 0 (**Minor Histocompatibility Antigens**)

L4 ANSWER 3 OF 13 MEDLINE
AN 96180356 MEDLINE
DN 96180356
TI Effect of metacycloprodigiosin, an inhibitor of killer T cells on murine skin and heart transplants.
AU Magae J; Miller M W; Nagai K; Shearer G M
CS Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
SO JOURNAL OF ANTIBIOTICS, (1996 Jan) 49 (1) 86-90.
Journal code: HCF. ISSN: 0021-8820.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 199608
AB Metacycloprodigiosin is an antibiotic that has been shown to suppress T-cell proliferation induced by concanavalin A in vitro. We examined the effect of metacycloprodigiosin on murine allogenic skin and heart transplantation models, and compared graft rejection with donor-specific cytotoxic T-cells and antibody activity. The antibiotic slightly prolonged the survival of C57Bl/6 heart and skin grafts in BALB/c mice, although the effect was less that that of cyclosporin A. The effect was more evident in Bm1 (H-2D mutant) skin grafts on C57Bl/6 hosts or in a **minor histocompatibility antigen**-mismatched model. In contrast, metacycloprodigiosin suppressed anti-graft cytotoxic T-cell activity of BALB/c spleen grafted with C57Bl/6 skin as comparable to cyclosporin A, but had only partial effect on antibody production. Thus, metacycloprodigiosin is more effective in reducing splenic cytotoxic T-cell activity than in prolonging murine skin or cardiac allografts.
CT Check Tags: Animal; Female
Cyclosporine: PD, pharmacology
Graft Survival: DE, drug effects
*Heart Transplantation: IM, immunology
*Immunosuppressive Agents: PD, pharmacology
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
***Prodigiosin: AA, analogs & derivatives**
Prodigiosin: PD, pharmacology
*Skin Transplantation: IM, immunology
*T-Lymphocytes, Cytotoxic: DE, drug effects
T-Lymphocytes, Cytotoxic: IM, immunology

RN 59865-13-3 (Cyclosporine); 82-89-3 (Prodigiosin)
CN 0 (metacycloprodigiosin); 0 (Immunosuppressive Agents)

L4 ANSWER 4 OF 13 MEDLINE
AN 95002951 MEDLINE
DN 95002951
TI Inhibition of nitric oxide production is associated with enhanced weight loss, decreased survival, and impaired alloengraftment in mice undergoing graft-versus-host disease after bone marrow transplantation.
AU Drobyski W R; Keever C A; Hanson G A; McAuliffe T; Griffith O W
CS Department of Medicine, Medical College of Wisconsin, Milwaukee 53226.
NC CA01534 (NCI)
SO BLOOD, (1994 Oct 1) 84 (7) 2363-73.
Journal code: A8G. ISSN: 0006-4971.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
EM 199501
AB The pathophysiologic role of nitric oxide (NO) in graft-versus-host disease (GVHD) was investigated in a murine bone marrow (BM) transplantation model where donor and recipient were H-2-matched but differed at multiple minor histocompatibility **antigens**. Host AKR/J (H-2K) mice received lethal total body irradiation as pretransplant conditioning followed by transplantation of donor B10.BR (H-2K) BM cells with or without spleen cells as a source of GVH-reactive T cells. NO production, as assessed by serum nitrate and nitrite levels, was increased for up to 3 weeks posttransplant in animals undergoing both moderate and severe GVHD. Administration of NG-methyl-L-arginine (L-NMA), an inhibitor of nitric oxide synthase, to animals undergoing GVHD resulted in effective suppression of NO production when compared with saline-treated GVHD control animals. Suppression of NO production by L-NMA in GVHD animals was associated with enhanced weight loss early posttransplant and decreased overall survival. Histologic analysis of tissues from L-NMA-treated and saline-treated GVHD animals showed that early weight loss was not because of an exacerbation of GVHD, indicating that NO did not appear to play an immunosuppressive role in this experimental model. L-NMA-treated animals with enhanced weight loss were observed to have splenic atrophy, decreased extramedullary hematopoiesis, and a reduction in BM cellularity when compared with GVHD control mice that were weight-matched before transplant. Analysis of T-cell chimerism in the spleen showed that L-NMA treatment impaired donor T-cell repopulation. In vitro colony-forming unit (CFU) assays were performed to further assess the role of NO on BM progenitor cell growth. L-NMA added directly into culture had no effect on CFU-granulocyte/macrophage (CFU-GM) formation in normal murine BM. In contrast, total CFU-GM from L-NMA-treated animals were significantly reduced when compared with GVHD controls or BM control animals who did not develop GVHD. Collectively, these data indicate that inhibition of NO impairs hematopoietic reconstitution and support the premise that NO appears to play a novel role in the facilitation of alloengraftment posttransplant.
CT Check Tags: Animal; Support, U.S. Gov't, P.H.S.
Amino Acid Oxidoreductases: AI, antagonists & inhibitors
Arginine: AA, analogs & derivatives
Arginine: PD, pharmacology

Body Weight: DE, drug effects
Bone Marrow: PA, pathology
*Bone Marrow Transplantation: PA, pathology
*Graft vs Host Disease: PA, pathology
Graft Survival
Mice
Mice, Inbred AKR
Minor Lymphocyte Stimulatory Antigens: IM, immunology
*Nitric Oxide: BI, biosynthesis
Spleen: PA, pathology
Survival Analysis

RN 10102-43-9 (Nitric Oxide); 17035-90-4 (omega-N-Methylarginine); 7004-12-8 (Arginine)

CN EC 1.14.13.39 (Nitric-Oxide Synthase); EC 1.4. (Amino Acid Oxidoreductases); 0 (Minor Lymphocyte Stimulatory Antigens)

L4 ANSWER 5 OF 13 MEDLINE

AN 86002336 MEDLINE

DN 86002336

TI **Minor histocompatibility antigens** are developmentally regulated on murine embryonal carcinoma cells and their early differentiated **derivatives**.

AU Avner P; Simmler M C

SO CELL DIFFERENTIATION, (1985 Aug) 17 (2) 115-23.
Journal code: CQ6. ISSN: 0045-6039.

CY Ireland

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 198601

AB Differences in the expression of minor histocompatibility (Hm) alloantigens on two mouse embryonal carcinoma (EC) cell lines and the PYS-2 and T.D.M.-1 differentiated **derivatives** have been demonstrated by their ability to elicit a cytolytic T lymphocyte response.

Experiments involving the use of various responder-target strain combinations and recombinant inbred mice strains have shown that: (1) there are major differences in Hm expression on EC cells compared with differentiated **derivatives** whose Hm expression appears more like that of adult splenocytes; (2) although both EC cell lines show reduced Hm immunogenicity compared with adult splenocytes, major differences in the expression and possible presentation of Hm between the F9 and PCC3 EC cell lines can be detected by in vivo priming and by in vitro cold competition target experiments. These observations are discussed in relation to the differences in allograft rejection patterns observed with PCC3 and F9 and to possible differences in developmental staging of these cell lines.

CT Check Tags: Animal
Cell Differentiation
Cell Line
Cytotoxicity, Immunologic
Immunization
Mice
Mice, Inbred Strains
*Minor Histocompatibility Loci
T-Lymphocytes, Cytotoxic: IM, immunology
*Teratoma: IM, immunology

Teratoma: PA, pathology
Yolk Sac: CY, cytology
Yolk Sac: IM, immunology

L4 ANSWER 6 OF 13 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
AN 97330017 EMBASE
DN 1997330017
TI Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis.
AU Shears II L.L.; Kawaharada N.; Tzeng E.; Billiar T.R.; Watkins S.C.; Kovesdi I.; Lizonova A.; Pham S.M.
CS Dr. S.M. Pham, Presbyterian University Hospital, 200 Lothrop Street, Pittsburgh, PA 15213, United States. pham@pittsurg.nb.upmc.edu
SO Journal of Clinical Investigation, (1997) 100/8 (2035-2042).
Refs: 48
ISSN: 0021-9738 CODEN: JCINAO
CY United States
DT Journal; Article
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index
LA English
SL English
AB In cardiac transplantation, chronic rejection takes the form of an occlusive vasculopathy. The mechanism underlying this disorder remains unclear. The purpose of this study was to investigate the role nitric oxide (NO) may play in the development of allograft arteriosclerosis. Rat aortic allografts from ACI donors to Wistar Furth recipients with a strong genetic disparity in both major and **minor histocompatibility antigens** were used for transplantation. Allografts collected at 28 d were found to have significant increases in both inducible NO synthase (iNOS) mRNA and protein as well as in intimal thickness when compared with isografts. Inhibiting NO production with an iNOS inhibitor increased the intimal thickening by 57.2%, indicating that NO suppresses the development of allograft arteriosclerosis. Next, we evaluated the effect of cyclosporine (CsA) on iNOS expression and allograft arteriosclerosis. CsA (10 mg/kg/d) suppressed the expression of iNOS in response to balloon-induced aortic injury. Similarly, CsA inhibited iNOS expression in the aortic allografts, associated with a 65% increase in intimal thickening. Finally, we investigated the effect of adenoviral- mediated iNOS gene transfer on allograft arteriosclerosis. Transduction with iNOS using an adenoviral vector suppressed completely the development of allograft arteriosclerosis in both untreated recipients and recipients treated with CsA. These results suggest that the early immune-mediated upregulation in iNOS expression partially protects aortic allografts from the development of allograft arteriosclerosis, and that iNOS gene transfer strategies may prove useful in preventing the development of this otherwise untreatable disease process.
CT Medical Descriptors:
*atherosclerosis: CO, complication
*atherosclerosis: PC, prevention
*atherosclerosis: ET, etiology
*graft rejection: PC, prevention
*graft rejection: ET, etiology
*graft rejection: DT, drug therapy

*graft rejection: CO, complication
*heart transplantation
adenovirus
allograft
animal model
animal tissue
artery intima proliferation: ET, etiology
artery intima proliferation: PC, prevention
artery intima proliferation: CO, complication
article
controlled study
enzyme induction
gene transfer
graft failure
immunosuppressive treatment
nonhuman
priority journal
rat
subcutaneous drug administration
virus vector
Drug Descriptors:
*cyclosporin a: DT, drug therapy
*nitric oxide: EC, endogenous compound
*nitric oxide synthase: EC, endogenous compound
immunosuppressive agent: DT, drug therapy
lysine derivative
messenger rna: EC, endogenous compound
RN (cyclosporin a) 59865-13-3, 63798-73-2; (nitric oxide) 10102-43-9; (nitric
oxide synthase) 125978-95-2

L4 ANSWER 7 OF 13 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
AN 94028927 EMBASE
DN 1994028927
TI Veto suppression: The peripheral way of T cell tolerization.
AU Tscherning T.; Claesson M.H.
CS Lab of Experimental Immunology, Institute of Medical Anatomy, The Panum Institute, Blegdamsvej 3C,DK-2200 Copenhagen N, Denmark
SO Experimental and Clinical Immunogenetics, (1993) 10/4 (179-188).
ISSN: 0254-9670 CODEN: ECIME4
CY Switzerland
DT Journal; General Review
FS 022 Human Genetics
026 Immunology, Serology and Transplantation
LA English
SL English
AB Cells with veto activity induce a state of tolerance in T cell precursors with specificity for antigen determinants expressed on the surface of the veto-active cell. This state of tolerance is not strictly defined, but results in altered responses to specific antigen, such as decreased proliferation, decreased development of cytotoxicity and secretion of interleukins, down-regulated ability to reject grafts and expression of T cell and IL-2 receptors. Both clonal anergy and clonal deletion has been shown to operate in vetoed T cells. Veto-induced tolerance can be established in vitro and in vivo for both MHC class I and II as well as **minor histocompatibility antigens**. The most powerful veto activity is present in mature activated cytotoxic CD8+ T cells, but other cells including noncytotoxic cells are also capable of

acting as veto cells. Thus it appears that veto activity per se is not confined to a certain cellular entity, but rather reflects a constitutively expressed immunoregulatory capability inherent to a broad array of activated T cell and non-T cell categories with their own distinct functions not related to their eventual veto activity.

CT Medical Descriptors:
*immunological tolerance
*immunoregulation
*t lymphocyte
clonal anergy
cell proliferation
cytotoxicity
graft rejection
lymphocyte clone
mouse
nonhuman
precursor cell
priority journal
protein secretion
review
Drug Descriptors:
t lymphocyte receptor
cd8 antigen: EC, endogenous compound
interleukin 2 receptor: EC, endogenous compound
interleukin derivative: EC, endogenous compound
major histocompatibility antigen class 1: EC, endogenous compound
major histocompatibility antigen class 2: EC, endogenous compound
membrane antigen: EC, endogenous compound

L4 ANSWER 8 OF 13 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1990:28060 BIOSIS
DN BA89:15026
TI PROTEIN-SPECIFIC CYTOTOXIC T LYMPHOCYTES RECOGNITION OF TRANSFECTANTS EXPRESSING INTRACELLULAR MEMBRANE-ASSOCIATED OR SECRETED FORMS OF BETA GALACTOSIDASE.
AU RAMMENSEE H-G; SCHILD H; THEOPOLD U
CS MAX-PLANCK-INST. BIOL., ABT. IMMUNGENETIK, CORRENSSTRASSE 42, D-7400 TUEBINGEN, FRG.
SO IMMUNOGENETICS, (1989) 30 (4), 296-302.
CODEN: IMNGBK. ISSN: 0093-7711.
FS BA; OLD
LA English
AB BALB/c-derived tumor cells were transfected with recombinant Escherichia coli .beta.-galactosidase (.beta.-gal) gene which were inserted into IgM heavy chain gene **derivatives**, leading to expression of the resulting fusion protein in different cellular compartments. A .beta.-gal-specific, major histocompatibility complex (MHC) class I-restricted CD8+ CD4- cytotoxic T lymphocyte (CTL) line of BALB/c origin raised against one transfectant expressing cytoplasmic .beta.-gal also lysed transfectants expressing .beta.-gal as membrane-inserted fusion protein, as well as transfectants secreting .beta.-gal. Our data show that
MHC class I-restricted CTL can recognize fragments of nonviral cellular proteins, be they expressed as intracellular, membrane-inserted, or secreted products. The findings confirm and extend a hypothesis on the nature of minor histocompatibility (H) antigens formulated earlier.
CC Cytology and Cytochemistry - Animal *02506
Biochemical Studies - Proteins, Peptides and Amino Acids 10064

Biophysics - Membrane Phenomena *10508
Enzymes - Physiological Studies *10808
Metabolism - Proteins, Peptides and Amino Acids *13012
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
BC Muridae 86375
IT Miscellaneous Descriptors
MOUSE MAJOR HISTOCOMPATIBILITY COMPLEX **MINOR HISTOCOMPATIBILITY ANTIGENS**
RN 9031-11-2 (BETA GALACTOSIDASE)

L4 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2001 ACS
AN 1999:96271 CAPLUS
DN 130:167164
TI The HA-1 antigen
IN Goulmy, Elsa Afra Julia Maria; Hunt, Donald F.; Engelhard, Victor H.
PA Rijksuniversiteit te Leiden, Neth.
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K014-705
ICS C07K016-28; A61K038-17
CC 15-2 (Immunochemistry)
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9905174	A1	19990204	WO 1998-NL425	19980723
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9885640	A1	19990216	AU 1998-85640	19980723

PRAI EP 1997-202303 19970723
WO 1998-N
L425 19980723

AB The present invention discloses the peptide sequence of a so called minor H antigen. The minor H antigens are assocd. with the graft vs. host disease. The peptide and its **derivs**. find many uses in bone marrow transplantation, organ transplantation and in the treatment of leukemia. The peptide and its **derivs**. can be incorporated in vaccines, in pharmaceutical formulations and they can be used in diagnostic test kits. The peptide is derived from the HA-1 minor antigen and has the sequence VLXDDLLEA, wherein X represents a histidine or an arginine residue. Both donors and recipients in bone marrow transplantation can be treated with the peptides, optionally in combination with other peptides, coupled to carriers, with suitable excipients and/or adjuvants.

ST **minor histocompatibility antigen** HA1 immune tolerance; T cell epitope HA1 antigen leukemia; graft vs host disease

IT **Minor histocompatibility antigens**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HA-1; T cell epitope obtainable from the **minor**

histocompatibility antigen HA-1 for induction of
immune tolerance and for treating transplant rejection, autoimmune
disease, neoplastic hematopoietic disease, and graft vs host disease)

IT Anti-idiotypic antibodies
Autoimmune diseases
B cell (lymphocyte)
Bone marrow transplant
Drug delivery systems
Graft vs. host reaction
Immune tolerance
Immunization
Immunological diseases
Leukemia
Mammal (Mammalia)
Medicine
Protein sequences
Transplant (organ)
Transplant rejection
Vaccines
(T cell epitope obtainable from the **minor**
histocompatibility antigen HA-1 for induction of
immune tolerance and for treating transplant rejection, autoimmune
disease, neoplastic hematopoietic disease, and graft vs host disease)

IT Antibodies
TCR (T cell receptors)
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)
(T cell epitope obtainable from the **minor**
histocompatibility antigen HA-1 for induction of
immune tolerance and for treating transplant rejection, autoimmune
disease, neoplastic hematopoietic disease, and graft vs host disease)

IT Class I HLA antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(T cell epitope obtainable from the **minor**
histocompatibility antigen HA-1 for induction of
immune tolerance and for treating transplant rejection, autoimmune
disease, neoplastic hematopoietic disease, and graft vs host disease)

IT Epitopes
(T cell; T cell epitope obtainable from the **minor**
histocompatibility antigen HA-1 for induction of
immune tolerance and for treating transplant rejection, autoimmune
disease, neoplastic hematopoietic disease, and graft vs host disease)

IT Test kits
(diagnostic; T cell epitope obtainable from the **minor**
histocompatibility antigen HA-1 for induction of
immune tolerance and for treating transplant rejection, autoimmune
disease, neoplastic hematopoietic disease, and graft vs host disease)

IT T cell (lymphocyte)
(epitope; T cell epitope obtainable from the **minor**
histocompatibility antigen HA-1 for induction of
immune tolerance and for treating transplant rejection, autoimmune
disease, neoplastic hematopoietic disease, and graft vs host disease)

IT Hematopoietic precursor cell
(tumors; T cell epitope obtainable from the **minor**
histocompatibility antigen HA-1 for induction of
immune tolerance and for treating transplant rejection, autoimmune
disease, neoplastic hematopoietic disease, and graft vs host disease)

IT 204931-32-8 220419-68-1

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(T cell epitope obtainable from the **minor histocompatibility antigen** HA-1 for induction of immune tolerance and for treating transplant rejection, autoimmune disease, neoplastic hematopoietic disease, and graft vs host disease)

RE.CNT 6

RE

(1) Den Haan, J; Eur J Immunol 1996, V26, P2680 CAPLUS
(2) Den Haan, J; Science 1995, V268, P1476 CAPLUS
(3) Den Haan, J; Science 1998, V279, P1054112
(4) Goulmy, E; WO 9705168 A 1997 CAPLUS
(5) Goulmy, E; WO 9705169 A 1997 CAPLUS
(6) Goulmy, E; Eye 1995, V9, P180

L4 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2001 ACS
AN 1999:96270 CAPLUS
DN 130:167163
TI The HA-1 antigen
IN Goulmy, Elsa Afra Julia Maria; Hunt, Donald Frederick; Engelhard, Victor Henry
PA Rijksuniversiteit te Leiden, Neth.
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K014-705
ICS C07K016-28; A61K038-17; C12N005-06
CC 15-2 (Immunochemistry)
Section cross-reference(s): 3

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9905173	A1	19990204	WO 1998-NL424	19980723
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9885639	A1	19990216	AU 1998-85639	19980723
EP 996636	A1	20000503	EP 1998-936758	19980723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				

PRAI EP 1997-202303 19970723
WO 1998-N
L424 19980723

AB The present invention discloses the peptide sequence of a so-called minor H antigen. The minor H antigens are assocd. with the graft vs. host disease. The peptide and its **derivs**. find many uses in bone marrow transplantation, organ transplantation and in the treatment of leukemia. The peptide and its **derivs**. can be incorporated in vaccines, in pharmaceutical formulations and they can be used in diagnostic test kits. The peptide is derived from the HA-1 minor antigen and has the sequence VLXDDLLEA, wherein X represents a histidine or an arginine residue. Both donors and recipients in bone marrow

transplantation can be treated with the peptides, optionally in combination with other peptides, coupled to carriers, with suitable excipients and/or adjuvants.

ST **minor histocompatibility antigen** HA1 immune tolerance; T cell epitope HA1 transplant rejection; graft vs host disease HA1 antigen

IT **Minor histocompatibility antigens**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HA-1; T cell epitope of **minor histocompatibility antigen** HA-1 for induction of immune tolerance and for treatment of transplant rejection, graft vs. host disease, leukemia and immune disease)

IT Genes (animal)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(KIAA0223; T cell epitope of **minor histocompatibility antigen** HA-1 for induction of immune tolerance and for treatment of transplant rejection, graft vs. host disease, leukemia and immune disease)

IT Anti-idiotypic antibodies
~~Autoimmune diseases~~
B cell (lymphocyte)
Bone marrow transplant
Cytotoxic T cell
Dendritic cell
Drug delivery systems
Epitopes
Graft vs. host reaction
Hematopoietic precursor cell
Immune tolerance
Immunization
Immunological diseases
Mammal (Mammalia)
Medicine
Polymorphism (genetic)
T cell (lymphocyte)
Transplant (organ)
Transplant rejection
Vaccines
(T cell epitope of **minor histocompatibility antigen** HA-1 for induction of immune tolerance and for treatment of transplant rejection, graft vs. host disease, leukemia and immune disease)

IT Antibodies
TCR (T cell receptors)
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(T cell epitope of **minor histocompatibility antigen** HA-1 for induction of immune tolerance and for treatment of transplant rejection, graft vs. host disease, leukemia and immune disease)

IT Class I HLA antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(T cell epitope of **minor histocompatibility**

antigen HA-1 for induction of immune tolerance and for
treatment of transplant rejection, graft vs. host disease, leukemia
and
immune disease)
IT Genes (animal)
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(suicide; T cell epitope of **minor histocompatibility**
antigen HA-1 for induction of immune tolerance and for
treatment of transplant rejection, graft vs. host disease, leukemia
and
immune disease)
IT Hematopoietic precursor cell
(tumors; T cell epitope of **minor histocompatibility**
antigen HA-1 for induction of immune tolerance and for
treatment of transplant rejection, graft vs. host disease, leukemia
and
immune disease)
IT 204931-32-8 220419-68-1
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(T cell epitope of **minor histocompatibility**
antigen HA-1 for induction of immune tolerance and for
treatment of transplant rejection, graft vs. host disease, leukemia
and
immune disease)
RE.CNT 7
RE
(1) Den Haan, J; Eur J Immunol 1996, V26, P2680 CAPLUS
(2) Den Haan, J; Science 1995, V268, P1476 CAPLUS
(3) Den Haan, J; Science 1998, V279, P1054 CAPLUS
(4) Goulmy, E; WO 9705168 A 1997 CAPLUS
(5) Goulmy, E; WO 9705169 A 1997 CAPLUS
(6) Goulmy, E; Eye 1995, V9, P180
(7) Van Der Harst, D; Blood 1994, V83(4), P1060 CAPLUS

L4 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2001 ACS
AN 1997:215796 CAPLUS
DN 126:198552
TI HA-2 antigenic peptide
IN Goulmy, Els A. J. M.; Hunt, Donald F.; Engelhard, Victor H.
PA Rijksuniversiteit Te Leiden, Neth.; University of Virginia Patent
Foundation; Goulmy, Els A. J. M.; Hunt, Donald F.; Engelhard, Victor H.
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K014-74
ICS C07K016-28; A61K038-16; C12N005-08
CC 15-2 (Immunochemistry)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9705169	A1	19970213	WO 1996-NL183	19960425

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT,
LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,

SG, SI
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN

US	5770201	A	19980623	US 1994-363691	19941223
CA	2224909	AA	19970213	CA 1996-2224909	19960425
AU	9654099	A1	19970226	AU 1996-54099	19960425
AU	716907	B2	20000309		
EP	840750	A1	19980513	EP 1996-911119	19960425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP	11514340	T2	19991207	JP 1996-507492	19960425

PRAI EP 1995-202039 19950725
WO 1996-N
L183 19960425

AB The present invention discloses the first peptide sequence of a so-called minor H antigen. The minor H antigens are assocd. with the Graft vs. Host Disease. The peptide and its **derivs**. find many uses in bone marrow transplantation, organ transplantation and in the treatment of leukemia. The peptide and its **derivs**. can be incorporated in vaccines, in pharmaceutical formulations and they can be used in diagnostic test kits. The peptide is derived from the HA-2 minor antigen and has the sequence IXGEVXVSV, wherein X represents a leucine or an isoleucine residue. Both donors and recipients in bone marrow transplantation can be treated with the peptides, optionally in combination with other peptides, coupled to carriers, with suitable excipients and/or adjuvants.

ST **minor histocompatibility antigen** HA2
transplant rejection

IT **Minor histocompatibility antigens**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HA-2; **minor histocompatibility antigen** HA-2 peptide for treating transplant rejection)

IT T cell (lymphocyte)
(epitope; **minor histocompatibility antigen** HA-2 peptide for treating transplant rejection)

IT B cell (lymphocyte)
Graft-vs.-host reaction
Immune tolerance
Leukemia
Protein sequences
Transplant rejection
Vaccines
(**minor histocompatibility antigen** HA-2 peptide for treating transplant rejection)

IT TCR (T-cell receptors)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**minor histocompatibility antigen** HA-2 peptide for treating transplant rejection)

IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**minor histocompatibility antigen** HA-2 peptide for treating transplant rejection)

IT Hematopoietic precursor cell
(tumors; **minor histocompatibility antigen** HA-2 peptide for treating transplant rejection)

IT 187944-95-2 187944-96-3 187944-97-4

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**minor histocompatibility antigen** HA-2 peptide for treating transplant rejection)

L4 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2001 ACS
AN 1990:1427 CAPLUS
DN 112:1427
TI Mapping minor H genes
AU Simpson, E.; Tomonari, K.
CS Transplant. Biol. Sect., MRC Clin. Res. Cent., Harrow/Middlesex, HA1 3UJ, UK
SO Immunology (1989), Suppl. 2, 42-9
CODEN: IMMUAM; ISSN: 0019-2805
DT Journal; General Review
LA English
CC 3-0 (Biochemical Genetics)
Section cross-reference(s): 13, 15
AB A review with 14 refs. The manner in which minor histocompatibility (H) antigens have been defined in mouse and man, in vivo and in vitro, is considered. Chromosomal mapping of minor H genes using T-cell clones is illustrated, with particular ref. to the H-Y antigen gene, using the sex-reversing translocation Sxr of mouse and the **deriv**. Sxr' mutation. A no. of minor H antigen-specific T-cell clones restricted by class I or class II major histocompatibility complex (MHC) mols. are described, together with information about their phenotypes and T-cell receptor usage.
ST histocompatibility H antigen gene mapping review
IT Gene and Genetic element, animal
RL: BIOL (Biological study)
(for **minor histocompatibility antigens**, mapping of)
IT Antigens
RL: BIOL (Biological study)
(H, genes for minor, mapping of)

L4 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2001 ACS
AN 1985:521308 CAPLUS
DN 103:121308
TI Differential Hm antigen expression on EC cells and early differentiated **derivatives**
AU Simmler, M. C.; Avner, P. R.
CS Unite Immunol. Virol. Tumeurs, Hop. Cochin, Paris, 75014, Fr.
SO EMBO J. (1985), 4(5), 1177-85
CODEN: EMJODG; ISSN: 0261-4189
DT Journal
LA English
CC 15-2 (Immunochemistry)
AB Differences in the expression of minor histocompatibility (Hm) alloantigens on 2 mouse embryonal carcinoma (EC) cell lines and the PYS-2 and T.D.M.-1 differentiated **derivs**. have been demonstrated by their ability to elicit a cytolytic T-lymphocyte (CTL) response. Expts. involving the use of various responder-target strain combinations on the one hand and recombinant inbred (RI) mice strains on the other have shown that: (i) there are major differences in Hm expression on the EC cells compared with the differentiated **derivs**. whose Hm expression appears more akin to that of adult splenocytes; (ii) although both EC cell

lines show reduced Hm immunogenicity compared with adult splenocytes, major differences in the expression and possibly presentation between the F9 and PCC3 EC cell lines can be detected both by in vivo priming and by in vitro cold competition target expts. These results are discussed in connection with the unexpected finding that some EC cell lines are capable of specific competition effects for appropriate CTL effectors despite their inability to stimulate such effectors in vitro and the absence of major histocompatibility complex products.

ST **minor histocompatibility antigen** embryonal carcinoma

IT Lymphocyte
(T-, cytolytic, **minor histocompatibility antigen** expression on embryonal carcinoma cells in relation to)

IT Carcinoma
(embryonal, **minor histocompatibility antigen** expression on, cytolytic T lymphocyte response in relation to)

IT Antigens
RL: BIOL (Biological study)
(minor histocompatibility, of embryonal carcinoma cells, cytolytic T lymphocyte response in relation to)

```
=> d his

     (FILE 'HOME' ENTERED AT 10:38:19 ON 12 FEB 2001)

     FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 10:38:50 ON
     12 FEB 2001
L1          2960 S MINOR HISTOCOMPATIBILITY ANTIGEN
L2            19 S L1 AND DERIVATIVE
L3            13 DUP REMOVE L2 (6 DUPLICATES REMOVED)
L4            13 S L3

=> s l1 and HA-1

L5          149 L1 AND HA-1

=> dup remove l5

PROCESSING COMPLETED FOR L5
L6            58 DUP REMOVE L5 (91 DUPLICATES REMOVED)

=> s l6 and VLXDDLLEA

L7             2 L6 AND VLXDDLLEA

=> d l7 all 1-2


L7   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2001 ACS
AN   1999:96271  CAPLUS
DN   130:167164
TI   The HA-1 antigen
IN   Goulmy, Elsa Afra Julia Maria; Hunt, Donald F.; Engelhard, Victor H.
PA   Rijksuniversiteit te Leiden, Neth.
```

SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K014-705
ICS C07K016-28; A61K038-17
CC 15-2 (Immunochemistry)
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9905174	A1	19990204	WO 1998-NL425	19980723
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9885640	A1	19990216	AU 1998-85640	19980723

PRAI EP 1997-202303 19970723
WO 1998-N
L425 19980723

AB The present invention discloses the peptide sequence of a so called minor H antigen. The minor H antigens are assocd. with the graft vs. host disease. The peptide and its derivs. find many uses in bone marrow transplantation, organ transplantation and in the treatment of leukemia. The peptide and its derivs. can be incorporated in vaccines, in pharmaceutical formulations and they can be used in diagnostic test kits. The peptide is derived from the **HA-1** minor antigen and has the sequence **VLXDDLLEA**, wherein X represents a histidine or an arginine residue. Both donors and recipients in bone marrow transplantation can be treated with the peptides, optionally in combination with other peptides, coupled to carriers, with suitable excipients and/or adjuvants.

ST **minor histocompatibility antigen** HA1 immune tolerance; T cell epitope HA1 antigen leukemia; graft vs host disease

IT **Minor histocompatibility antigens**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**HA-1**; T cell epitope obtainable from the **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treating transplant rejection, autoimmune disease, neoplastic hematopoietic disease, and graft vs host disease)

IT Anti-idiotypic antibodies
Autoimmune diseases
B cell (lymphocyte)
Bone marrow transplant
Drug delivery systems
Graft vs. host reaction
Immune tolerance
Immunization
Immunological diseases
Leukemia
Mammal (Mammalia)
Medicine
Protein sequences

Transplant (organ)
Transplant rejection
Vaccines
(T cell epitope obtainable from the **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treating transplant rejection, autoimmune disease, neoplastic hematopoietic disease, and graft vs host disease)

IT Antibodies
TCR (T cell receptors)
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(T cell epitope obtainable from the **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treating transplant rejection, autoimmune disease, neoplastic hematopoietic disease, and graft vs host disease)

IT Class I HLA antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(T cell epitope obtainable from the **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treating transplant rejection, autoimmune disease, neoplastic hematopoietic disease, and graft vs host disease)

IT Epitopes
(T cell; T cell epitope obtainable from the **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treating transplant rejection, autoimmune disease, neoplastic hematopoietic disease, and graft vs host disease)

IT Test kits
(diagnostic; T cell epitope obtainable from the **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treating transplant rejection, autoimmune disease, neoplastic hematopoietic disease, and graft vs host disease)

IT T cell (lymphocyte)
(epitope; T cell epitope obtainable from the **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treating transplant rejection, autoimmune disease, neoplastic hematopoietic disease, and graft vs host disease)

IT Hematopoietic precursor cell
(tumors; T cell epitope obtainable from the **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treating transplant rejection, autoimmune disease, neoplastic hematopoietic disease, and graft vs host disease)

IT 204931-32-8 220419-68-1
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(T cell epitope obtainable from the **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treating transplant rejection, autoimmune disease, neoplastic hematopoietic disease, and graft vs host disease)

RE.CNT 6
RE

(1) Den Haan, J; Eur J Immunol 1996, V26, P2680 CAPLUS
(2) Den Haan, J; Science 1995, V268, P1476 CAPLUS
(3) Den Haan, J; Science 1998, V279, P1054112
(4) Goulmy, E; WO 9705168 A 1997 CAPLUS
(5) Goulmy, E; WO 9705169 A 1997 CAPLUS
(6) Goulmy, E; Eye 1995, V9, P180

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2001 ACS
AN 1999:96270 CAPLUS
DN 130:167163
TI The **HA-1** antigen
IN Goulmy, Elsa Afra Julia Maria; Hunt, Donald Frederick; Engelhard, Victor Henry
PA Rijksuniversiteit te Leiden, Neth.
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K014-705
ICS C07K016-28; A61K038-17; C12N005-06
CC 15-2 (Immunochemistry)
Section cross-reference(s): 3

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9905173	A1	19990204	WO 1998-NL424	19980723
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9885639	A1	19990216	AU 1998-85639	19980723
EP 996636	A1	20000503	EP 1998-936758	19980723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				

PRAI EP 1997-202303 19970723
WO 1998-N
L424 19980723

AB The present invention discloses the peptide sequence of a so-called minor H antigen. The minor H antigens are assocd. with the graft vs. host disease. The peptide and its derivs. find many uses in bone marrow transplantation, organ transplantation and in the treatment of leukemia. The peptide and its derivs. can be incorporated in vaccines, in pharmaceutical formulations and they can be used in diagnostic test kits. The peptide is derived from the **HA-1** minor antigen and has the sequence **VLXDDLLEA**, wherein X represents a histidine or an arginine residue. Both donors and recipients in bone marrow transplantation can be treated with the peptides, optionally in combination with other peptides, coupled to carriers, with suitable excipients and/or adjuvants.

ST **minor histocompatibility antigen** HA1 immune tolerance; T cell epitope HA1 transplant rejection; graft vs host disease HA1 antigen

IT **Minor histocompatibility antigens**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(**HA-1**; T cell epitope of **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treatment of transplant rejection, graft vs. host disease, leukemia and immune disease)

IT Genes (animal)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(KIAA0223; T cell epitope of **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treatment of transplant rejection, graft vs. host disease, leukemia and immune disease)

IT Anti-idiotypic antibodies
Autoimmune diseases
B cell (lymphocyte)
Bone marrow transplant
Cytotoxic T cell
Dendritic cell
Drug delivery systems
Epitopes
Graft vs. host reaction
Hematopoietic precursor cell
Immune tolerance
Immunization
Immunological diseases
Mammal (Mammalia)
Medicine
Polymorphism (genetic)
T cell (lymphocyte)
Transplant (organ)
Transplant rejection
Vaccines
(T cell epitope of **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treatment of transplant rejection, graft vs. host disease, leukemia and immune disease)

IT Antibodies
TCR (T cell receptors)
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(T cell epitope of **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treatment of transplant rejection, graft vs. host disease, leukemia and immune disease)

IT Class I HLA antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(T cell epitope of **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treatment of transplant rejection, graft vs. host disease, leukemia and immune disease)

IT Genes (animal)
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suicide; T cell epitope of **minor histocompatibility antigen HA-1** for induction of immune tolerance and for treatment of transplant rejection, graft vs. host disease, leukemia and immune disease)

IT Hematopoietic precursor cell
(tumors; T cell epitope of **minor histocompatibility**

antigen HA-1 for induction of immune
tolerance and for treatment of transplant rejection, graft vs. host
disease, leukemia and immune disease)
IT 204931-32-8 220419-68-1
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(T cell epitope of **minor histocompatibility**
antigen HA-1 for induction of immune
tolerance and for treatment of transplant rejection, graft vs. host
disease, leukemia and immune disease)
RE.CNT 7
RE
(1) Den Haan, J; Eur J Immunol 1996, V26, P2680 CAPLUS
(2) Den Haan, J; Science 1995, V268, P1476 CAPLUS
(3) Den Haan, J; Science 1998, V279, P1054 CAPLUS
(4) Goulmy, E; WO 9705168 A 1997 CAPLUS
(5) Goulmy, E; WO 9705169 A 1997 CAPLUS
(6) Goulmy, E; Eye 1995, V9, P180
(7) Van Der Harst, D; Blood 1994, V83(4), P1060 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 10:38:19 ON 12 FEB 2001)

FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 10:38:50 ON
12 FEB 2001
L1 2960 S MINOR HISTOCOMPATIBILITY ANTIGEN
L2 19 S L1 AND DERIVATIVE
L3 13 DUP REMOVE L2 (6 DUPLICATES REMOVED)
L4 13 S L3
L5 149 S L1 AND HA-1
L6 58 DUP REMOVE L5 (91 DUPLICATES REMOVED)
L7 2 S L6 AND VLXDDLLEA

=> s l5 and VLHDDLLEA

L8 8 L5 AND VLHDDLLEA

=> dup remove l8

PROCESSING COMPLETED FOR L8
L9 2 DUP REMOVE L8 (6 DUPLICATES REMOVED)

=> d l8 1-2

L8 ANSWER 1 OF 8 MEDLINE
AN 2000166344 MEDLINE
DN 20166344
TI Molecular modeling of the **minor histocompatibility**
antigen HA-1 peptides binding to HLA-A
alleles.
AU Ren E C; Kangueane P; Kolatkar P; Lin M T; Tseng L H; Hansen J A
CS Department of Microbiology, WHO Collaborating Center for Immunology,
National University of Singapore, Singapore.. micrenec@nus.edu.sg

SO TISSUE ANTIGENS, (2000 Jan) 55 (1) 24-30.
Journal code: VSV. ISSN: 0001-2815.
CY Denmark
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200005
EW 20000502

L8 ANSWER 2 OF 8 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
AN 2000049501 EMBASE
TI Molecular modeling of the **minor histocompatibility antigen HA-1** peptides binding to HLA-A alleles.
AU Ren E.C.; Kangueane P.; Kolatkar P.; Lin M.T.; Tseng L.H.; Hansen J.A.
CS Dr. E.C. Ren, Department of Microbiology, Faculty of Medicine, National University Singapore, Singapore 119260, Singapore. micrenec@nus.edu.sg
SO Tissue Antigens, (2000) 55/1 (24-30).
Refs: 20
ISSN: 0001-2815 CODEN: TSANA2
CY Denmark
DT Journal; Article
FS 022 Human Genetics
026 Immunology, Serology and Transplantation
LA English
SL English

=> d his

(FILE 'HOME' ENTERED AT 10:38:19 ON 12 FEB 2001)

FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 10:38:50 ON 12 FEB 2001
L1 2960 S MINOR HISTOCOMPATIBILITY ANTIGEN
L2 19 S L1 AND DERIVATIVE
L3 13 DUP REMOVE L2 (6 DUPLICATES REMOVED)
L4 13 S L3
L5 149 S L1 AND HA-1
L6 58 DUP REMOVE L5 (91 DUPLICATES REMOVED)
L7 2 S L6 AND VLXDDLLEA
L8 8 S L5 AND VLHDDLLEA
L9 2 DUP REMOVE L8 (6 DUPLICATES REMOVED)

=> s l5 and VLRDDLLEA

L10 5 L5 AND VLRDDLLEA

=> dup remove l10

PROCESSING COMPLETED FOR L10
L11 1 DUP REMOVE L10 (4 DUPLICATES REMOVED)

=> D l11

L11 ANSWER 1 OF 1 MEDLINE DUPLICATE 1

AN 2000166344 MEDLINE
DN 20166344
TI Molecular modeling of the **minor histocompatibility antigen HA-1** peptides binding to HLA-A alleles.
AU Ren E C; Kangueane P; Kolatkar P; Lin M T; Tseng L H; Hansen J A
CS Department of Microbiology, WHO Collaborating Center for Immunology, National University of Singapore, Singapore.. micrenec@nus.edu.sg
SO TISSUE ANTIGENS, (2000 Jan) 55 (1) 24-30.
Journal code: VSV. ISSN: 0001-2815.
CY Denmark
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200005
EW 20000502

=> d his

(FILE 'HOME' ENTERED AT 10:38:19 ON 12 FEB 2001)

FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 10:38:50 ON 12 FEB 2001
L1 2960 S MINOR HISTOCOMPATIBILITY ANTIGEN
L2 19 S L1 AND DERIVATIVE
L3 13 DUP REMOVE L2 (6 DUPLICATES REMOVED)
L4 13 S L3
L5 149 S L1 AND HA-1
L6 58 DUP REMOVE L5 (91 DUPLICATES REMOVED)
L7 2 S L6 AND VLXDDLLEA
L8 8 S L5 AND VLHDDLLEA
L9 2 DUP REMOVE L8 (6 DUPLICATES REMOVED)
L10 5 S L5 AND VLRDDLLEA
L11 1 DUP REMOVE L10 (4 DUPLICATES REMOVED)

=> s l1 and HA-2

L12 55 L1 AND HA-2

=> dup remove L12

PROCESSING COMPLETED FOR L12
L13 17 DUP REMOVE L12 (38 DUPLICATES REMOVED)

=> d l13 1-17

L13 ANSWER 1 OF 17 SCISEARCH COPYRIGHT 2001 ISI (R)
AN 2001:76463 SCISEARCH
GA The Genuine Article (R) Number: 372WB
TI Emergence of hematopoiesis-specific **minor histocompatibility antigen** (mHag) HA-1 and **HA-2** specific CD8+T cells associated with complete molecular remission after donor lymphocyte infusion (DLI) for relapsed CML.
AU Marijt W A F (Reprint); Kester M G D; Goulmy E; Mutis T; Drijfhout J W; Willemze R; Falkenburg J H F

CS Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Immunohematol, Leiden, Netherlands
CYA Netherlands
SO BLOOD, (16 NOV 2000) Vol. 96, No. 11, Part 1, pp. 478A-478A. MA 2055. Publisher: AMER SOC HEMATOLOGY, 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA.
ISSN: 0006-4971.
DT Conference; Journal
LA English
REC Reference Count: 0

L13 ANSWER 2 OF 17 MEDLINE DUPLICATE 1
AN 1999192451 MEDLINE
DN 99192451
TI Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted **minor histocompatibility antigens** [see comments].
CM Comment in: Blood 1999 Dec 15;94(12):4374-6
AU Mutis T; Verdijk R; Schrama E; Esendam B; Brand A; Goulmy E
CS Department of Immunohematology and Blood Bank, Leiden University Medical Center, Leiden, The Netherlands.. Mutis@rullf2.leidenuniv.nl
SO BLOOD, (1999 Apr 1) 93 (7) 2336-41.
Journal code: A8G. ISSN: 0006-4971.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
EM 199906

L13 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2001 ACS
AN 1997:215796 CAPLUS
DN 126:198552
TI **HA-2** antigenic peptide
IN Goulmy, Els A. J. M.; Hunt, Donald F.; Engelhard, Victor H.
PA Rijksuniversiteit Te Leiden, Neth.; University of Virginia Patent Foundation; Goulmy, Els A. J. M.; Hunt, Donald F.; Engelhard, Victor H.
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9705169	A1	19970213	WO 1996-NL183	19960425
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	US 5770201	A	19980623	US 1994-363691	19941223
	CA 2224909	AA	19970213	CA 1996-2224909	19960425
	AU 9654099	A1	19970226	AU 1996-54099	19960425
	AU 716907	B2	20000309		
	EP 840750	A1	19980513	EP 1996-911119	19960425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				

JP 11514340 T2 19991207 JP 1996-507492 19960425
PRAI EP 1995-202039 19950725
WO 1996-N
L183 19960425

L13 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2001 ACS
AN 2000:6100 CAPLUS
DN 132:292279
TI Nature of the **minor histocompatibility antigens**
AU Goulmy, E.
CS Department of Immunohaematology and Blood Bank, University Hospital, Leiden, 2300 RC, Neth.
SO HLA: [Proc. Int. Histocompat. Workshop Conf.], 12th (1997), Meeting Date 1996, Volume 2, 39-41. Editor(s): Charron, Dominique. Publisher: EDK, Medical and Scientific International Publisher, Sevres, Fr. CODEN: 68MRA5
DT Conference; General Review
LA English
RE.CNT 10
RE
(2) Den Haan, J; Eur J Immunol 1996, V26, P2680 CAPLUS
(3) Den Haan, J; Science 1995, V268, P1476 CAPLUS
(6) Goulmy, E; Curr Op Immunol 1996, V8, P75 CAPLUS
(9) Van der Harst, D; Blood 1994, V83, P1060 CAPLUS
(10) Wang, W; Science 1995, V269, P1588 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 17 MEDLINE DUPLICATE 2
AN 97080610 MEDLINE
DN 97080610
TI Conservation of **minor histocompatibility antigens** between human and non-human primates.
AU den Haan J M; Bontrop R E; Pool J; Sherman N; Blokland E; Engelhard V H; Hunt D F; Goulmy E
CS Department of Immunohaematology and Bloodbank, Leiden University Hospital, The Netherlands.. haan.j@rulgca.leidenuniv.nl
NC AI20963 (NIAID)
AI33993 (NIAID)
SO EUROPEAN JOURNAL OF IMMUNOLOGY, (1996 Nov) 26 (11) 2680-5. Journal code: EN5. ISSN: 0014-2980.
CY GERMANY: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Cancer Journals; Priority Journals
EM 199703

L13 ANSWER 6 OF 17 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1996:111037 BIOSIS
DN PREV199698683172
TI Mismatches of **minor histocompatibility antigens** between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation.
AU Goulmy, Els (1); Schipper, Ronald; Pool, Jos; Blokland, Els; Falkenburg, J. H. Frederick; Vossen, Jaak; Gratwohl, Alois; Vogelsang, Georgia B.; Van

Houwelingen, Hans C.; Van Rood, Jon J.
CS (1) Dep. Immunohematology Blood Bank, Leiden Univ. Hosp., P.O. Box 9600, 2300 RC Leiden Netherlands
SO New England Journal of Medicine, (1996) Vol. 334, No. 5, pp. 281-285. ISSN: 0028-4793.
DT Article
LA English

L13 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2001 ACS
AN 1996:532658 CAPLUS
DN 125:193403
TI Functional expression of **minor histocompatibility antigens** on human peripheral blood dendritic cells and epidermal Langerhans cells
AU Van Lochem, Ellen; Van Der Keur, Maarten; Mommaas, A. Mieke; De Gast, Gijsbert C.; Goulmy, Els
CS Department Immunohematology and Bloodbank, Leiden University Hospital, Leiden, 2300 RC, Neth.
SO Transplant Immunol. (1996), 4(2), 151-157
CODEN: TRIME2; ISSN: 0966-3274
DT Journal
LA English

L13 ANSWER 8 OF 17 MEDLINE DUPLICATE 3
AN 95288637 MEDLINE
DN 95288637
TI Identification of a graft versus host disease-associated human **minor histocompatibility antigen.**
AU den Haan J M; Sherman N E; Blokland E; Huczko E; Koning F; Drijfhout J W; Skipper J; Shabanowitz J; Hunt D F; Engelhard V H; et al
CS Department of Immunohaematology, University Hospital, Leiden, Netherlands.
NC AI33993 (NIAID)
AI20963 (NIAID)
SO SCIENCE, (1995 Jun 9) 268 (5216) 1476-80.
Journal code: UJ7. ISSN: 0036-8075.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 199509

L13 ANSWER 9 OF 17 MEDLINE DUPLICATE 4
AN 95362850 MEDLINE
DN 95362850
TI Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ **minor histocompatibility antigen**-specific cytotoxic T lymphocytes.
AU Faber L M; van der Hoeven J; Goulmy E; Hooftman-den Otter A L; van Luxemburg-Heijs S A; Willemze R; Falkenburg J H
CS Department of Hematology, University Medical Center, Leiden, The Netherlands..
SO JOURNAL OF CLINICAL INVESTIGATION, (1995 Aug) 96 (2) 877-83.
Journal code: HS7. ISSN: 0021-9738.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English

FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
EM 199511

L13 ANSWER 10 OF 17 MEDLINE DUPLICATE 5
AN 94333484 MEDLINE
DN 94333484
TI Presentation of viral antigens restricted by H-2Kb, Db or Kd in proteasome subunit LMP2- and LMP7-deficient cells.
AU Zhou X; Momburg F; Liu T; Abdel Motal U M; Jondal M; Hammerling G J; Ljunggren H G
CS Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden.
SO EUROPEAN JOURNAL OF IMMUNOLOGY, (1994 Aug) 24 (8) 1863-8.
Journal code: EN5. ISSN: 0014-2980.
CY GERMANY: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 199411

L13 ANSWER 11 OF 17 MEDLINE DUPLICATE 6
AN 94154267 MEDLINE
DN 94154267
TI Recognition of **minor histocompatibility antigens** on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones.
AU van der Harst D; Goulmy E; Falkenburg J H; Kooij-Winkelaar Y M; van Luxemburg-Heijs S A; Goselink H M; Brand A
CS Department of Immunohematology and Bloodbank, University Medical Center, Leiden, The Netherlands..
SO BLOOD, (1994 Feb 15) 83 (4) 1060-6.
Journal code: A8G. ISSN: 0006-4971.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
EM 199406

L13 ANSWER 12 OF 17 MEDLINE DUPLICATE 7
AN 94083660 MEDLINE
DN 94083660
TI **Minor histocompatibility antigens** HA-1-, -2-, and -4-, and HY-specific cytotoxic T-cell clones inhibit human hematopoietic progenitor cell growth by a mechanism that is dependent on direct cell-cell contact.
AU Marijt W A; Veenhof W F; Goulmy E; Willemze R; van Rood J J; Falkenburg J H
CS Department of Hematology, University Medical Center, Leiden, The Netherlands..
SO BLOOD, (1993 Dec 15) 82 (12) 3778-85.
Journal code: A8G. ISSN: 0006-4971.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
EM 199403

L13 ANSWER 13 OF 17 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 8
AN 93095092 EMBASE
DN 1993095092
TI Isolation of an HLA-A2.1 extracted human minor histocompatibility peptide.
AU De Bueger M.; Verreck F.; Blokland E.; Drijfhout J.W.; Amous R.; Koning F.; Goulmy E.
CS Department of Immunohaematology, University Hospital Leiden, Rijnsburgerweg 10,NL-2333 AA Leiden, Netherlands
SO European Journal of Immunology, (1993) 23/3 (614-618).
ISSN: 0014-2980 CODEN: EJIMAF
CY Germany
DT Journal; Article
FS 026 Immunology, Serology and Transplantation
029 Clinical Biochemistry
LA English
SL English

L13 ANSWER 14 OF 17 MEDLINE DUPLICATE 9
AN 93246305 MEDLINE
DN 93246305
TI A genetic analysis of human **minor histocompatibility antigens** demonstrates Mendelian segregation independent of HLA.
AU Schreuder G M; Pool J; Blokland E; van Els C; Bakker A; van Rood J J; Goulmy E
CS Department of Immunohaematology, University Hospital Leiden, The Netherlands..
SO IMMUNOGENETICS, (1993) 38 (2) 98-105.
Journal code: GI4. ISSN: 0093-7711.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 199308

L13 ANSWER 15 OF 17 MEDLINE DUPLICATE 10
AN 92373026 MEDLINE
DN 92373026
TI Tissue distribution of human **minor histocompatibility antigens**. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens.
AU de Bueger M; Bakker A; Van Rood J J; Van der Woude F; Goulmy E
CS Department of Immunohaematology, University Hospital, Leiden, The Netherlands..
SO JOURNAL OF IMMUNOLOGY, (1992 Sep 1) 149 (5) 1788-94.
Journal code: IFB. ISSN: 0022-1767.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
EM 199211

L13 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2001 ACS
AN 1992:233346 CAPLUS
DN 116:233346
TI Transfected human class I gene product adequately assembles **minor**

histocompatibility antigens
AU Goulmy, Els; Pool, Jos; Blokland, Els; Geraghty, Dan
CS Dep. Immunohaematol., Univ. Hosp., Leiden, 2300 RC, Neth.
SO Immunogenetics (1991), 34(4), 270-2
CODEN: IMNGBK; ISSN: 0093-7711
DT Journal
LA English

L13 ANSWER 17 OF 17 MEDLINE DUPLICATE 11
AN 89067836 MEDLINE
DN 89067836
TI Cellularly defined **minor histocompatibility antigens** are differentially expressed on human hematopoietic progenitor cells.
AU Voogt P J; Goulmy E; Veenhof W F; Hamilton M; Fibbe W E; Van Rood J J; Falkenburg J H
CS Department of Hematology, University Medical Center, Leiden, The Netherlands..
SO JOURNAL OF EXPERIMENTAL MEDICINE, (1988 Dec 1) 168 (6) 2337-47.
Journal code: I2V. ISSN: 0022-1007.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 198903

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	66.79	66.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.12	-4.12

STN INTERNATIONAL LOGOFF AT 10:50:41 ON 12 FEB 2001